Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer
Dipeptidyl peptidase (DPP- 4) inhibitors belong to the oral antidiabetic drugs. They are used for the treatment of Type 2 Diabetes mellitus. DPP-4 is an enzyme which puts down the action of hormone, incretin. Incretins belong to the group of hypoglycaemic gastrointestinal hormones. Some studies show...
Gespeichert in:
| Veröffentlicht in: | Diabetes & metabolic syndrome clinical research & reviews 2019-01, Vol.13 (1), p.36-39 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 39 |
|---|---|
| container_issue | 1 |
| container_start_page | 36 |
| container_title | Diabetes & metabolic syndrome clinical research & reviews |
| container_volume | 13 |
| creator | Almagthali, Alaa G. Alkhaldi, Eman H. Alzahrani, Afnan S. Alghamdi, Ameera K. Alghamdi, Waleed Y. Kabel, Ahmed M. |
| description | Dipeptidyl peptidase (DPP- 4) inhibitors belong to the oral antidiabetic drugs. They are used for the treatment of Type 2 Diabetes mellitus. DPP-4 is an enzyme which puts down the action of hormone, incretin. Incretins belong to the group of hypoglycaemic gastrointestinal hormones. Some studies show that DPP-4 inhibitors causes cancer and some study show that they have anticancer property. This review sheds light on the role of the different types of DPP-4 inhibitors in cancer therapy. |
| doi_str_mv | 10.1016/j.dsx.2018.08.012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2179367018</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1871402118303175</els_id><sourcerecordid>2179367018</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-11864c9d605fff40544f6c3293bb0b39079f5fd9850ba7579ea05cce03c9f1ba3</originalsourceid><addsrcrecordid>eNp9kEtLLDEQhYNc8f0D3EiWd9NjpdPp7lxXMj5BcKO4DOmkohl6utsk4-PfGx2vS-FAFdQ5B-oj5JDBjAGrjxczG99mJbB2Blms3CA7rG3aAjiv_nztrKigZNtkN8YFgBCylFtkm0Ndsaasd8jDmZ9wSt6-93S96IhFRf3w5DufxhD_0dMh-cJ63WHyhtqweoz01acnOo0J8033FJ1DkyIdB2r0YDDsk02n-4gH33OP3F-c382vipvby-v56U1huOCpYKytKyNtDcI5V4GoKlcbXkreddBxCY10wlnZCuh0IxqJGoQxCNxIxzrN98jfde8UxucVxqSWPhrsez3guIqqZI3kdZMRZStbW00YYwzo1BT8Uod3xUB98lQLlXmqT54KsliZM0ff9atuifYn8R9gNpysDZiffPEYVDQeMwHrQyai7Oh_qf8AGleGSA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2179367018</pqid></control><display><type>article</type><title>Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer</title><source>Elsevier ScienceDirect Journals</source><creator>Almagthali, Alaa G. ; Alkhaldi, Eman H. ; Alzahrani, Afnan S. ; Alghamdi, Ameera K. ; Alghamdi, Waleed Y. ; Kabel, Ahmed M.</creator><creatorcontrib>Almagthali, Alaa G. ; Alkhaldi, Eman H. ; Alzahrani, Afnan S. ; Alghamdi, Ameera K. ; Alghamdi, Waleed Y. ; Kabel, Ahmed M.</creatorcontrib><description>Dipeptidyl peptidase (DPP- 4) inhibitors belong to the oral antidiabetic drugs. They are used for the treatment of Type 2 Diabetes mellitus. DPP-4 is an enzyme which puts down the action of hormone, incretin. Incretins belong to the group of hypoglycaemic gastrointestinal hormones. Some studies show that DPP-4 inhibitors causes cancer and some study show that they have anticancer property. This review sheds light on the role of the different types of DPP-4 inhibitors in cancer therapy.</description><identifier>ISSN: 1871-4021</identifier><identifier>EISSN: 1878-0334</identifier><identifier>DOI: 10.1016/j.dsx.2018.08.012</identifier><identifier>PMID: 30641726</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Cancer ; Diabetes mellitus ; Dipeptidyl peptidase-4 inhibitors ; Patients</subject><ispartof>Diabetes & metabolic syndrome clinical research & reviews, 2019-01, Vol.13 (1), p.36-39</ispartof><rights>2018 Diabetes India</rights><rights>Copyright © 2018 Diabetes India. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-11864c9d605fff40544f6c3293bb0b39079f5fd9850ba7579ea05cce03c9f1ba3</citedby><cites>FETCH-LOGICAL-c353t-11864c9d605fff40544f6c3293bb0b39079f5fd9850ba7579ea05cce03c9f1ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1871402118303175$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30641726$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Almagthali, Alaa G.</creatorcontrib><creatorcontrib>Alkhaldi, Eman H.</creatorcontrib><creatorcontrib>Alzahrani, Afnan S.</creatorcontrib><creatorcontrib>Alghamdi, Ameera K.</creatorcontrib><creatorcontrib>Alghamdi, Waleed Y.</creatorcontrib><creatorcontrib>Kabel, Ahmed M.</creatorcontrib><title>Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer</title><title>Diabetes & metabolic syndrome clinical research & reviews</title><addtitle>Diabetes Metab Syndr</addtitle><description>Dipeptidyl peptidase (DPP- 4) inhibitors belong to the oral antidiabetic drugs. They are used for the treatment of Type 2 Diabetes mellitus. DPP-4 is an enzyme which puts down the action of hormone, incretin. Incretins belong to the group of hypoglycaemic gastrointestinal hormones. Some studies show that DPP-4 inhibitors causes cancer and some study show that they have anticancer property. This review sheds light on the role of the different types of DPP-4 inhibitors in cancer therapy.</description><subject>Cancer</subject><subject>Diabetes mellitus</subject><subject>Dipeptidyl peptidase-4 inhibitors</subject><subject>Patients</subject><issn>1871-4021</issn><issn>1878-0334</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kEtLLDEQhYNc8f0D3EiWd9NjpdPp7lxXMj5BcKO4DOmkohl6utsk4-PfGx2vS-FAFdQ5B-oj5JDBjAGrjxczG99mJbB2Blms3CA7rG3aAjiv_nztrKigZNtkN8YFgBCylFtkm0Ndsaasd8jDmZ9wSt6-93S96IhFRf3w5DufxhD_0dMh-cJ63WHyhtqweoz01acnOo0J8033FJ1DkyIdB2r0YDDsk02n-4gH33OP3F-c382vipvby-v56U1huOCpYKytKyNtDcI5V4GoKlcbXkreddBxCY10wlnZCuh0IxqJGoQxCNxIxzrN98jfde8UxucVxqSWPhrsez3guIqqZI3kdZMRZStbW00YYwzo1BT8Uod3xUB98lQLlXmqT54KsliZM0ff9atuifYn8R9gNpysDZiffPEYVDQeMwHrQyai7Oh_qf8AGleGSA</recordid><startdate>201901</startdate><enddate>201901</enddate><creator>Almagthali, Alaa G.</creator><creator>Alkhaldi, Eman H.</creator><creator>Alzahrani, Afnan S.</creator><creator>Alghamdi, Ameera K.</creator><creator>Alghamdi, Waleed Y.</creator><creator>Kabel, Ahmed M.</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201901</creationdate><title>Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer</title><author>Almagthali, Alaa G. ; Alkhaldi, Eman H. ; Alzahrani, Afnan S. ; Alghamdi, Ameera K. ; Alghamdi, Waleed Y. ; Kabel, Ahmed M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-11864c9d605fff40544f6c3293bb0b39079f5fd9850ba7579ea05cce03c9f1ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Cancer</topic><topic>Diabetes mellitus</topic><topic>Dipeptidyl peptidase-4 inhibitors</topic><topic>Patients</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Almagthali, Alaa G.</creatorcontrib><creatorcontrib>Alkhaldi, Eman H.</creatorcontrib><creatorcontrib>Alzahrani, Afnan S.</creatorcontrib><creatorcontrib>Alghamdi, Ameera K.</creatorcontrib><creatorcontrib>Alghamdi, Waleed Y.</creatorcontrib><creatorcontrib>Kabel, Ahmed M.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes & metabolic syndrome clinical research & reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Almagthali, Alaa G.</au><au>Alkhaldi, Eman H.</au><au>Alzahrani, Afnan S.</au><au>Alghamdi, Ameera K.</au><au>Alghamdi, Waleed Y.</au><au>Kabel, Ahmed M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer</atitle><jtitle>Diabetes & metabolic syndrome clinical research & reviews</jtitle><addtitle>Diabetes Metab Syndr</addtitle><date>2019-01</date><risdate>2019</risdate><volume>13</volume><issue>1</issue><spage>36</spage><epage>39</epage><pages>36-39</pages><issn>1871-4021</issn><eissn>1878-0334</eissn><abstract>Dipeptidyl peptidase (DPP- 4) inhibitors belong to the oral antidiabetic drugs. They are used for the treatment of Type 2 Diabetes mellitus. DPP-4 is an enzyme which puts down the action of hormone, incretin. Incretins belong to the group of hypoglycaemic gastrointestinal hormones. Some studies show that DPP-4 inhibitors causes cancer and some study show that they have anticancer property. This review sheds light on the role of the different types of DPP-4 inhibitors in cancer therapy.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>30641726</pmid><doi>10.1016/j.dsx.2018.08.012</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1871-4021 |
| ispartof | Diabetes & metabolic syndrome clinical research & reviews, 2019-01, Vol.13 (1), p.36-39 |
| issn | 1871-4021 1878-0334 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2179367018 |
| source | Elsevier ScienceDirect Journals |
| subjects | Cancer Diabetes mellitus Dipeptidyl peptidase-4 inhibitors Patients |
| title | Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T08%3A59%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dipeptidyl%20peptidase-4%20inhibitors:%20Anti-diabetic%20drugs%20with%20potential%20effects%20on%20cancer&rft.jtitle=Diabetes%20&%20metabolic%20syndrome%20clinical%20research%20&%20reviews&rft.au=Almagthali,%20Alaa%20G.&rft.date=2019-01&rft.volume=13&rft.issue=1&rft.spage=36&rft.epage=39&rft.pages=36-39&rft.issn=1871-4021&rft.eissn=1878-0334&rft_id=info:doi/10.1016/j.dsx.2018.08.012&rft_dat=%3Cproquest_cross%3E2179367018%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2179367018&rft_id=info:pmid/30641726&rft_els_id=S1871402118303175&rfr_iscdi=true |